Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Tung, R.    Shah, P. K.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Narrative Review: Drug-Eluting Stents for the Management of Restenosis: A Critical Appraisal of the Evidence

Roderick Tung, MD; Sanjay Kaul, MD; George A. Diamond, MD; and Prediman K. Shah, MD

20 June 2006 | Volume 144 Issue 12 | Pages 913-919

Interventional cardiologists have quickly replaced bare metal stents with intravascular drug-eluting stents for treating and preventing restenosis, largely on the basis of empirical evidence that shows profound reduction in angiographic and clinical restenosis. A critical reassessment of the published evidence, however, suggests that the putative superiority of intravascular drug-eluting stents is founded on questionable premises, including 1) overestimation of restenosis benefit, 2) underestimation of the risk for stent thrombosis, 3) overreliance on "soft" rather than "hard" outcomes (need for repeated revascularization vs. death or myocardial infarction), and 4) the attendant overestimation of cost-effectiveness. Because the long-term incremental risks, benefits, and costs of drug-eluting stents have not yet been optimally evaluated in a broad spectrum of patient and lesion cohorts, the rational role of these devices in clinical management warrants reappraisal.

Author and Article Information

From Cedars-Sinai Medical Center, David Geffen School of Medicine, and University of California, Los Angeles, Los Angeles, California.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Sanjay Kaul, MD, Division of Cardiology, Room 5536, South Tower, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.

Current Author Addresses: Drs. Tung, Kaul, Diamond, and Shah: Division of Cardiology, Room 5536, South Tower, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.

This article has been cited by other articles:

				H. Ramakrishna, G. Godet, Y. Le Manach, F. Lesache, S. Perbet, and P. Coriat Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery Br. J. Anaesth., July 1, 2008; 101(1): 130 - 130. [Full Text] [PDF]

				D. Austin, J. P. Pell, K. G. Oldroyd, P. Agostoni, P. Vermeersch, O. C. Marroquin, S. R. Mulukutla, and K. E. Kip Bare-metal versus drug-eluting coronary stents. N. Engl. J. Med., June 5, 2008; 358(23): 2516 - 2517. [Full Text] [PDF]

				J. D. Ketcham and M. F. Furukawa Hospital-Physician Gainsharing In Cardiology Health Aff., May 1, 2008; 27(3): 803 - 812. [Abstract] [Full Text] [PDF]

				D. P. Taggart, S. Kaul, W. E. Boden, T. B. Ferguson Jr, R. A. Guyton, M. J. Mack, P. T. Sergeant, R. J. Shemin, P. K. Smith, and S. Yusuf Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 885 - 892. [Abstract] [Full Text] [PDF]

				A. Jeremias and A. Kirtane Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention Ann Intern Med, February 5, 2008; 148(3): 234 - 238. [Abstract] [Full Text] [PDF]

				D. Austin, J. P Pell, and K. G Oldroyd Drug-eluting stents: do the risks really outweigh the benefits? Heart, February 1, 2008; 94(2): 127 - 128. [Full Text] [PDF]

				R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]

				G. A. Diamond and S. Kaul COURAGE Under Fire: On the Management of Stable Coronary Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1604 - 1609. [Abstract] [Full Text] [PDF]

				P. H. Giangrande, J. Zhang, A. Tanner, A. D. Eckhart, R. E. Rempel, E. R. Andrechek, J. M. Layzer, J. R. Keys, P.-O. Hagen, J. R. Nevins, et al. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia PNAS, August 7, 2007; 104(32): 12988 - 12993. [Abstract] [Full Text] [PDF]

				S. Kaul, P. K. Shah, and G. A. Diamond As Time Goes By: Current Status and Future Directions in the Controversy Over Stenting J. Am. Coll. Cardiol., July 10, 2007; 50(2): 128 - 137. [Abstract] [Full Text] [PDF]

				P. Keul, M. Tolle, S. Lucke, K. von Wnuck Lipinski, G. Heusch, M. Schuchardt, M. van der Giet, and B. Levkau The Sphingosine-1-Phosphate Analogue FTY720 Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 607 - 613. [Abstract] [Full Text] [PDF]

				Drug-Eluting Stents: A Critical Reassessment Journal Watch Cardiology, August 9, 2006; 2006(809): 4 - 4. [Full Text]